Weight Loss Pills vs Injections: What the Evidence Actually Shows

What are the key differences between weight loss pills and injections available in the UK?

There is a common assumption that pills are the milder, easier option and injections are somehow more serious or medical. That framing is worth setting aside, because the distinction that actually matters is pharmacological, not psychological.

The injections currently licensed for weight management in the UK are Mounjaro (tirzepatide, made by Eli Lilly) and Wegovy (semaglutide injection, made by Novo Nordisk). Mounjaro activates two gut-hormone receptors (GIP and GLP-1) slowing gastric emptying and reducing appetite. Wegovy acts on the GLP-1 receptor alone. Both are once-weekly subcutaneous injections, delivered via pre-filled pens into the abdomen, thigh or upper arm. You can read more about how weight loss injections work in detail.

The pill option is Wegovy tablets (oral semaglutide), which the MHRA approved on 11 June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK. It contains the same active molecule as the Wegovy injection, co-formulated with an absorption enhancer (SNAC) to allow it to survive the digestive process. It is taken once daily, first thing in the morning on an empty stomach, with a small amount of plain water, at least 30 minutes before food or any other oral medicine. No refrigeration is needed, which makes it straightforwardly travel-friendly.

Ozempic and Rybelsus are also semaglutide products but are licensed for type 2 diabetes, not weight management, they are not appropriate to seek for weight loss purposes, and our prescribers do not prescribe them for that reason.

How do the results compare between pills and injections for weight loss?

Trial evidence matters here, so it is worth being precise about what each medicine has demonstrated. The figures below come from randomised controlled trials; individual results in practice vary.

A few things are worth drawing out. The injection form of semaglutide and the tablet form contain the same molecule, but oral bioavailability of semaglutide is lower, which is reflected in the trial results: around 13.6% average loss versus around 15% for the 2.4mg weekly injection in comparable populations. The ~16.6% figure for the tablet applies specifically to participants who stayed fully adherent throughout the OASIS 4 trial, it should not be read as the typical result. Tirzepatide's injection produced the largest average losses across all the licensed options, and in the SURMOUNT-5 head-to-head trial (published in the New England Journal of Medicine, 2025) it produced greater average weight reduction than semaglutide 2.4mg over 72 weeks. You can explore how pills compare to injections for effectiveness in more depth, and there is also a useful breakdown of which form tends to suit which person.

Does the practical experience of taking a pill or an injection differ much day to day?

For many people the day-to-day difference is the deciding factor, and it is a reasonable thing to weigh up.

Weekly injections mean one administration per week, which some people find surprisingly easy to build into a routine. Storage requires a fridge. Used pens and needles need safe disposal, a sharps container handles this straightforwardly. The technique itself is simple: a small-gauge needle, a pinch of skin, a slow press. Most people who felt nervous about it beforehand report that anxiety fading quickly.

The daily tablet asks for more consistency around timing: every morning, before eating or drinking anything other than a small amount of water, at least 30 minutes before the rest of your morning routine. That is a real discipline, and adherence matters more than with a once-weekly injection. On the other hand, there is no cold-chain storage, no sharps disposal and nothing to carry in a cool bag when travelling.

Side effects across both forms are predominantly gastrointestinal (nausea, changes in digestion, occasional fatigue) and tend to be most noticeable after starting or after a dose increase, often settling over days to a couple of weeks. The pill vs injection side-effect profile is broadly similar given the shared mechanism, though gastrointestinal effects were reported in around 74% of tablet users in the OASIS 4 trial versus about 42% in the placebo group, which is worth knowing in advance. The NHS tirzepatide medicine page and NHS semaglutide medicine page both cover side effects clearly and are worth reading before you start either form.

Which form might suit me, and how does a prescriber decide?

Neither form is universally better. The weight loss injections tend to show larger average reductions in trials, tirzepatide particularly so, but a person who cannot adhere to a weekly injection routine (or who genuinely cannot manage injections) may do better in practice with a tablet they take every morning. Adherence over months matters more than the theoretical ceiling of any trial.

Prescribers look at the full picture: your BMI, any weight-related conditions, your other medicines (oral contraceptives and oral HRT, for instance, interact differently with tirzepatide than with semaglutide, so the form and route of other medicines you take is clinically relevant), your lifestyle, and your own preference. There is no algorithm that spits out the right answer. For anyone curious about the options beyond injections, whether pills can substitute for injections is a question worth exploring with a prescriber directly.

Both Mounjaro and Wegovy (injection and tablet) require a prescription following clinical assessment. If cost is part of your thinking, the cost of weight loss injections page sets out how private pricing works and what a legitimate price should include. And if the idea of a rolling subscription gives you pause, it is worth knowing that treatment without automatic subscription is how nume operates: every repeat order is reviewed individually. Which form suits you is a clinical decision our prescribers make with you.